American Association for Cancer Research
10780432ccr161357-sup-167052_1_supp_3672271_gdrf4s.docx (325.94 kB)

Supplementary Figure 3 from Neoadjuvant Enzalutamide Prior to Prostatectomy

Download (325.94 kB)
journal contribution
posted on 2023-03-31, 19:40 authored by Bruce Montgomery, Maria S. Tretiakova, Anthony M. Joshua, Martin E. Gleave, Neil Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel W. Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W. Kantoff, Brett T. Marck, Stephen Plymate, Steven P. Balk, Peter S. Nelson, Alvin M. Matsumoto, Rosina T. Lis, Adam Kibel, Gabriel P. Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin

Figure S3. Change in serum androgen levels after enza or enza/dut/LHRHa. Box plots of serum androgens for each cohort at initiation of therapy (day 0) and at prostatectomy (day 180) are depicted for each treatment arm. Levels of (A) pregnenolone, (B) progesterone, (C) DHEA, (D) AED, (E) testosterone, and (F) DHT were measured by mass spectroscopy. P values were calculated using the nonparametric Mann-Whitney test. Limits of quantification were 0.005 ng/mL for AED, progesterone and testosterone, 0.001 ng/mL for DHT and pregnenolone, and 0.15 ng/mL for DHEA.


Pacific Northwest Prostate Cancer

Dana-Farber Cancer Institute Prostate Cancer

Prostate Cancer Foundation



Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enzalutamide or enza/dut/LHRHa for 6 months. We assessed pathologic complete response (pCR), minimal residual disease (MRD; ≤3 mm maximum diameter of residual disease), residual cancer burden (RCB), and expression of PSA and serum and tissue androgen concentrations. We compared the proportion of patients with pCR in each treatment arm with a historical control rate of 5%, based on previous reports of flutamide with LHRHa.Results: In the enzalutamide arm, none of the 25 patients achieved pCR or MRD. In the enza/dut/LHRHa arm, one of 23 patients (4.3%) achieved pCR and 3 of 23 (13.0%) achieved MRD. Median RCB was higher in the enzalutamide arm than in the enza/dut/LHRHa arm (0.41 cm3 vs. 0.06 cm3, respectively). Tissue testosterone and dihydrotestosterone levels correlated with RCB. No adverse events leading to study drug discontinuation were reported.Conclusions: Combination therapy with enza/dut/LHRHa resulted in pCR and MRD rates comparable with historical controls. Evidence of continued AR activity in residual tumor suggests that AR signaling may contribute to survival. Strategies to more effectively ablate AR activity are warranted to determine whether more substantial antitumor effects are observed. Clin Cancer Res; 23(9); 2169–76. ©2016 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager